simtuzumab
mAbexperimental
Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. — Wikipedia
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
11
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01323933)
Timeline
Indications
Studied for
Mechanism of action
- Lysyl oxidase homolog 2INHIBITOR
LOXL2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSimtuzumab ↗
- ChEMBLCHEMBL2109667 ↗
Also known as
- ab0024
- ab-0024
- gs-6624
- gs-6624
- gs-6624
- gs-6624
- simtuzumab
- simtuzumab
- simtuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02466516 | Phase 2 | Jun 1, 2015 | Gilead Sciences |
| NCT01672853 | Phase 2 | Feb 1, 2013 | Gilead Sciences |
| NCT01769196 | Phase 2 | Jan 31, 2013 | Gilead Sciences |
| NCT01672866 | Phase 2 | Dec 5, 2012 | Gilead Sciences |
| NCT01672879 | Phase 2 | Oct 29, 2012 | Gilead Sciences |
| NCT01759511 | Phase 2 | Oct 18, 2012 | Gilead Sciences |
| NCT01707472 | Phase 2 | Aug 1, 2012 | Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01479465 | Phase 2 | Dec 1, 2011 | Gilead Sciences |
| NCT01472198 | Phase 2 | Nov 1, 2011 | Gilead Sciences |
| NCT01452308 | Phase 2 | Nov 1, 2011 | Gilead Sciences |
| NCT01369498 | Phase 2 | Jun 1, 2011 | Gilead Sciences |
| NCT01362231 | Phase 1 | Dec 1, 2010 | Gilead Sciences |
| NCT01323933 | Phase 1 | Jun 1, 2010 | Gilead Sciences, South Texas Accelerated Research Therapeutics, Wayne State University |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 13 | 13 | 2 | 2010 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2012 |
| South Texas Accelerated Research Therapeutics | For profit | 1 | 0 | 1 | 2010 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1